Paraneoplastic neurological

PARANEOPLASTIC NEUROLOGICAL SYNDROMES AND ONCONEURAL ANTIBODIES CLINICAL AND IMMUNOLOGICAL ASPECTS... 

Cancer patients often develop symptoms from organs remote from the primary tumor. The symptoms are usually caused by metastasis or toxic effects of therapy and less often by such secondary factors as nutritional deficiency, metabolic disturbances, opportunistic infections, and effects of critical illness. Other systemic diseases such as diabetes or amyloid may become manifest or aggravated during the course of the cancer disease and cause symptoms from remote organs. Paraneoplastic neurological syndromes (PNS) are a rare cause of remote symptoms [1]. The PNS affect less than 1% of all cancer patients [2], Even in small cell lung cancer (SCLC), the tumor type most commonly associated with PNS, these disorders occur in less than 5% of the patients [3, 4],... 

Bataller L, Dalmau J. Paraneoplastic neurologic syndromes. Neurol Clin 2003 21(1) 221-247. ix. 

Roberts WK, Darnell RB. Neuroimmunology of the paraneoplastic neurological degenerations. Curr Opin Immunol 2004 16(5) 616-622. 

Rauer S, Andreou I. Tumor progression and serum anti-HuD antibody concentration in patients with paraneoplastic neurological syndromes. Eur Neurol 2002 47(4) 189-195. 

Voltz R. Paraneoplastic neurological syndromes An update on diagnosis, pathogenesis, and therapy. Lancet Neurol 2002 1(5) 294—305. 

Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neuro-surg Psychiatry 2004 75(8) 1135—1140. 

Anderson NE, Cunningham JM, Posner JB. Autoimmune pathogenesis of paraneoplastic neurological syndromes. Crit Rev Neurobiol 1987 3(3) 245-299. 

Musunuru K, Darnell RB. Paraneoplastic neurologic disease antigens RNA-binding proteins and signaling proteins in neuronal degeneration. Annu Rev Neurosci 2001 24 239-262. 

Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, et al. Mai, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999 122(Pt. l) 27-39. 

Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996 61(3) 270-278. 

Sutton I. Paraneoplastic neurological syndromes. Curr Opin Neurol 2002 15(6) 685-690. 

Rojas-Marcos I, Rousseau A, Keime-Guibert F, Rene R, Cartalat-Carel S, Delattre JY, et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 2003 82(3) 216-223. 

Floyd S, Butler MH, Cremona O, David C, Freyberg Z, Zhang X, et al. Expression of amphiphysin I, an autoantigen of paraneoplastic neurological syndromes, in breast cancer. Mol Med 1998 4(l) 29-39. 

Sutton I, Winer JB. The immunopathogenesis of paraneoplastic neurological syndromes. Clin Sci (Lond) 2002 102(5)475-486. 

Honnorat J, Cartalat-Carel S. Advances in paraneoplastic neurological syndromes. Curr Opin Oncol 2004 16(6) 614-620. 

Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004 127(Pt. 10) 2331-2338. 

Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes Value of CT and PET for tumor diagnosis. Neurology 2004 63(2) 282-286. 

Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanche JP, Confavreux C, et al. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 2000 48(1) 105-108. 

Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, et al. The role of [18F] fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001 124(Pt. 11) 2223-2231. 

Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders At the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA 1996 93(10) ... 

Moll JW, Antoine JC, Brashear HR, Delattre J, Drlicek M, Dropcho EJ, et al. Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies Report from the Workshop to the Fourth Meeting of the International Society of Neuro-Immunology on paraneoplastic neurological disease, held October 22-23, 1994, in Rotterdam, The Netherlands. Neurology 1995 45(10) 1937-1941. 

Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, et al. Antiamphi-physin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 1999 56(2) 172-177. 

Sillevis-Smitt P, Manley G, Moll JW, Dalmau J, Posner JB. Pitfalls in the diagnosis of autoantibodies associated with paraneoplastic neurologic disease. Neurology 1996 46(6) 1739-1741. 

Rauer S, Kaiser R. Enzyme linked immunosorbent assay using recombinant HuD-auto-antigen for serodiagnosis of paraneoplastic neurological syndromes. Acta Neurol Scand 2001 103(4) 248-254. 

Drlicek M, Bianchi G, Bogliun G, Casati B, Grisold W, Kolig C, et al. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes A longterm survey of ovarian cancer patients. J Neurol 1997 244(2) 85-89. 

Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, et al. Anti-glial nuclear antibody Marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005 165(1—2) 166—171. 

Schafer KH, Klotz M, Mergner D, Mestres P, Schimrigk K, Blaes F. IgG-mediated cytotoxicity to myenteric plexus cultures in patients with paraneoplastic neurological syndromes. J Autoimmun 2000 15(4) 479-484. 

Tanaka K, Ding X, Tanaka M. Effects of antineuronal antibodies from patients with paraneoplastic neurological syndrome on primary-cultured neurons. J Neurol Sci 2004 217(1) 25—30. 

---